If the Market Crashes, This Is the 1 Space Stock I Can't Wait to Buy

Rocket Lab reported record Q2 revenue of $234 million, up 62% year over year, while backlog rose 137% to $2.36 billion and new launch contracts exceeded $437 million. Recent U.S. Space Force awards total $663 million, including a $266 million suborbital-launch contract and a $397 million spacecraft build-and-launch contract. The bullish outlook depends on successful execution of the larger reusable Neutron rocket, though the company remains unprofitable and carries a roughly $40 billion valuation, or about 50x trailing sales.

Analysis

RKLB’s investment case is shifting from a launch-frequency narrative to an execution-and-capital-allocation narrative. Government work can improve demand visibility, but it may also carry milestone, fixed-price, and working-capital risk; backlog conversion is not equivalent to high-margin revenue conversion. The key second-order issue is whether space-systems revenue funds development or merely absorbs overhead while Neutron capex accelerates, because that distinction determines whether the company can avoid another dilutive financing cycle.

Near term, the equity remains a high-duration risk asset rather than a defense proxy: a broad rates/risk-off move should compress its revenue multiple materially faster than large defense primes. Over the next 1-3 months, investors should focus on quarterly cash burn, gross-margin progression, and any change in Neutron schedule or estimated development spend; contract announcements alone are unlikely to support the current premium. Over 6-18 months, a credible path to first Neutron launch and repeatable manufacturing throughput is the catalyst for multiple durability, while schedule slips would likely re-rate RKLB toward space-hardware rather than platform economics.

Consensus appears to treat vertical integration as unambiguously favorable. It can create customer lock-in and higher lifetime mission revenue, but it also makes RKLB responsible for more supply-chain execution, inventory, warranty, and mission-assurance liabilities. The non-obvious upside is that successful government mission execution could lower customer concentration risk and improve financing access; the corresponding downside is that one high-profile failure would impair both launch and spacecraft-component cross-sell simultaneously.

Key Decisions for Investors

• Do not chase RKLB on contract headlines. Establish a watch-level long only after a broad-market drawdown or valuation reset, with preferred entry contingent on management reaffirming Neutron timing and showing sequential improvement in operating cash burn; target a 12-18 month holding period.
• For existing RKLB exposure, own downside protection through 3-6 month put spreads rather than adding spot exposure ahead of the next earnings update. The thesis is falsified by a material Neutron schedule extension, a step-up in annual cash burn without offsetting funded milestones, or evidence that new awards are dilutive to consolidated gross margin.
• Use a relative-value expression for space/defense exposure: long RKLB in a modest size versus short XAR or an equal-dollar basket of LMT/NOC only after a selloff. This isolates RKLB-specific execution upside while limiting broad defense-budget and market-beta exposure; unwind if the relative spread tightens before a verifiable development milestone.
• Track procurement disclosures for contract type, funding profile, and option exercise terms. Treat any large award lacking funded backlog, milestone-payment detail, or margin commentary as an alert rather than a buy catalyst.